Skip to main content
SpringerLink
Log in

Antiplatelet Therapy in Interventional Cardiology: II. Glycoprotein IIb/IIIa Inhibitors

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680–1688.

    PubMed  Google Scholar 

  2. Kleiman N, Ohman E, Califf R, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;1993:381–389.

    Google Scholar 

  3. Platelet Receptor Inhibition in Ischemic SyndromeManagement (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–505.

    Google Scholar 

  4. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.

    Google Scholar 

  5. Tirofiban in unstable coronary disease [letter]. N Engl J Med 1998;339:1163–1165.

  6. Granger C, Miller J, Bovill E, et al. Rebound increase in thrombin generation activity after cessation of intravenous heparin in patients with acute coronary syndromes. 91 1995:1929–1935.

    Google Scholar 

  7. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436–443.

    Google Scholar 

  8. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral ASA, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.

    Google Scholar 

  9. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615–1622.

    Google Scholar 

  10. Simes R, Topol E, Holmes D, et al. for the GUSTO-I Investigators. The link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: The importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923–1928.

    PubMed  Google Scholar 

  11. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997;95:1755–1759.

    PubMed  Google Scholar 

  12. Kleiman N, Ohman E, Califf R, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Allergy Clin Immunol 1993;22:381–389.

    Google Scholar 

  13. Ohman E, Kleiman N, Gacioch G, et al. for the IMPACTAMI investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997;95:846–854.

    Google Scholar 

  14. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998;32: 2003–2010.

    Google Scholar 

  15. Antman E, Guigliano R, McCabe C, et al. Abciximab (Reo-Pro) potentiates thrombolysis in ST-elevation myocardial infarction: Results of TIMI-14 trial. J Am Coll Cardiol 1998;31(Suppl. A):191A.

    Google Scholar 

  16. Alexander J, Kong D. Session highlights from the European Society of Cardiology XXth Annual Congress: August 22 to 26, 1998. Am Heart J 1999;137:180–186.

    PubMed  Google Scholar 

  17. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330(14): 956–961.

    Google Scholar 

  18. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343: 881–886.

    PubMed  Google Scholar 

  19. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479–484.

    PubMed  Google Scholar 

  20. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689–1696.

    Google Scholar 

  21. Lincoff M, Tcheng J, Califf R, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One year outcome in the EPILOG trial. Circulation. 1999;99:1951–1958.

    PubMed  Google Scholar 

  22. The IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II (Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis II). Lancet 1997;349:1422–1428.

    Google Scholar 

  23. The RESTORE investigators. Effects of platelet glycoprotein IIb/III blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997:1445–1453.

    Google Scholar 

  24. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429–1435.

    Google Scholar 

  25. Serruys P, deJaegere P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489–495.

    PubMed  Google Scholar 

  26. Fischman DL, Leon MB, Baim DS, et al. for the Stent Restenosis Study Investigators. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331:496–501.

    PubMed  Google Scholar 

  27. Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG trial investigators. Circulation 1998;97: 857–864.

    PubMed  Google Scholar 

  28. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87–92.

    Google Scholar 

  29. Topol E, Byzovk T, Plow E. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227–231.

    Article  PubMed  Google Scholar 

  30. Schwartz L, Lesperance J, Bourassa MG, et al. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty. Am Heart J 1990;119:232–236.

    PubMed  Google Scholar 

  31. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714–1719.

    Google Scholar 

  32. O'Neill W, Brodie B, Ivanhoe R, et al. Primary coronary angioplasty for acute myocardial infarction (the primary angioplasty registry). Am J Cardiol 1994:627–634.

  33. Mabin TA, Holmes DR, Jr., Smith HC, et al. Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;5:198–202.

    PubMed  Google Scholar 

  34. Mooney MR, Mooney JF, Goldenberg IF, Almquist AK, Van Tassel RA. Percutaneous transluminal coronary angioplasty in the setting of large intracoronary thrombi. Am J Cardiol 1990;65:427–431.

    PubMed  Google Scholar 

  35. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the “no reflow” phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223–228.

    PubMed  Google Scholar 

  36. Rawitscher D, Levin T, Cohen I, Feldman T. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997;42:187–190.

    PubMed  Google Scholar 

  37. Neuman F, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695–2701.

    PubMed  Google Scholar 

  38. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996;77:1045–1051.

    PubMed  Google Scholar 

  39. Aguirre F, Topol E, Ferguson J, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882–2890.

    PubMed  Google Scholar 

  40. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734–741.

    PubMed  Google Scholar 

  41. Azar R, McKay R, Thompson P, et al. Abciximab in primary coronary angioplasty for acute myocardial infarction improves short-and medium-term outcomes. J Am Coll Cardiol 1998;32:1996–2002.

    PubMed  Google Scholar 

  42. Montalescot G. ADMIRAL: Abciximab with PTCA and Stent in Acute Myocardial Infarction Oral presentation 48th Annual Scientific Sessions of the American College of Cardiology, 1999.

  43. Grayburn P, Willard J, Bruckner M, Eichhorn E. In vivo thrombus formation on a guidewire during intravacular ultrasound imaging: Evidence for inadequate heparinization. Cathet Cardiovasc Diagn 1991;23:141–143.

    PubMed  Google Scholar 

  44. Young J, Kisker C, Dory D. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231–240.

    PubMed  Google Scholar 

  45. Narins C, Hillegass WJ, Nelson C, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:660–671.

    PubMed  Google Scholar 

  46. Ferguson J, Dougherty K, Gaos C, Bush H, Marsh K, Leachman D. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061–1065.

    PubMed  Google Scholar 

  47. Frierson J, Dimas A, Simpfendorfer C, Pearce G, Miller M, Fracno I. Is aggressive heparinization necssary for elective PTCA? Cathet Cardiovasc Diagn 1993;28:279–282.

    PubMed  Google Scholar 

  48. Popma J, Satler L, Pichard A, et al. Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569–1578.

    PubMed  Google Scholar 

  49. Brener S, DeLuca S, Rouses C, Juran N, Brezina K, Ellis S. Planned versus “rescue” abciximab during angioplasty: Inhospital outcomes (abstr). Circulation 1996;90:I375.

    Google Scholar 

  50. Kereiakes D, Broderick T, Whang D, Anderson L, Fye D. Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. Am J Cardiol 1997;80:633–634.

    PubMed  Google Scholar 

  51. Pan M, de Lezo J, Medina A, et al. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation. Am J Cardiol 1997;80:1336–1338.

    PubMed  Google Scholar 

  52. Rabah M, Cannon L, Weiner B, Kugelmass A, Hundley R, Muller D. Heparin After Percutaneous Intervention (HAPI): Preliminary results of a prospective multicenter randomized trial. Circulation 1996;94:I198.

    Google Scholar 

  53. Friedman H, Cragg D, Glazier S, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angiopalasty. J Am Coll Cardiol. 1994;24:1214–1219.

    PubMed  Google Scholar 

  54. Ellis S, Roubin G, Wilentz J, Douglas JJ, King SI. Effect of 18–24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777–782.

    PubMed  Google Scholar 

  55. Pizzulli L, Zirbes M, Fehske W, Pfeiffer D. Omission of intravenous heparin and nitroglycerin following uncomplicated coronary angioplasty: A prospective, randomized trial (abstr). Circulation 1995;92(Suppl. I):I74.

    Google Scholar 

  56. Garachemani A, Kaufmann U, Fleisch M, Meier B. Prolonged heparin after uncomplicated coronary interventions: A prospective, randomized trial. Am Heart J 1998;136: 352–356.

    PubMed  Google Scholar 

  57. Hall P, Namamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93: 215–222.

    PubMed  Google Scholar 

  58. Leon M, Baim D, Gordon P, et al. for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med 1998;339:1665–1671.

    Google Scholar 

  59. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998;98: 1597–1603.

    Google Scholar 

  60. Jafary F, Kimmelstiel C. Antiplatelet drug therapy in interventional cardiology. Part I. J Thromb Thrombolys 2000; 7:157–162.

    Google Scholar 

  61. Urban P, Macaya C, Rupprecht H, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998;98:2126–2132.

    PubMed  Google Scholar 

  62. Zidar J. Low-molecular-weight heparins in coronary stenting (The ENTICES Trial). Am J Cardiol 1998;82:29L–32L.

    PubMed  Google Scholar 

  63. Kelton J, Sheridan D, Brian H, Powers P, Turpie A, Carter C. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984;103:606–612.

    PubMed  Google Scholar 

  64. Berkowitz S, Harrington R, Rund M, Tcheng J. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809–13.

    Google Scholar 

  65. Data on file, Centocor Inc.

  66. Christopoulos C, Machin S. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimeric antibody. Br J Haematol 1994;87:650–652.

    PubMed  Google Scholar 

  67. Van Belle E, Lablanche J, Bauters C, et al. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis. Circulation 1998;97:26–33.

    PubMed  Google Scholar 

  68. O'Neill W. EXCITE Trial: Efficacy and safety of xemilo-fiban, an oral IIb/IIIa platelet inhibitor, in patients undergoing PTCA or stent placement Oral presentation, 48th Annual Scientific Sessions of the American College of Cardiology, 1999.

  69. Kong D, Califf R, Miller D, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa Integrin in ischemic heart disease. Circulation 1998;98: 2829–2835.

    PubMed  Google Scholar 

  70. Ellis S, Lincoff M, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol 1998;32: 1619–1623.

    PubMed  Google Scholar 

  71. Chesebro J, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142–154.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiac Catheterization Laboratory, Division of Cardiology, New England Medical Center, Boston, Massachusetts, USA

    Fahim H. Jafary & Carey D. Kimmelstiel

Authors
  1. Fahim H. Jafary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carey D. Kimmelstiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jafary, F.H., Kimmelstiel, C.D. Antiplatelet Therapy in Interventional Cardiology: II. Glycoprotein IIb/IIIa Inhibitors. J Thromb Thrombolysis 9, 163–174 (2000). https://doi.org/10.1023/A:1018775015882

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018775015882

Search

Navigation